Other Clinical Trial - Using Mobile Technology to Reduce Stereotypy

Status Completed

Clinical Trial Summary

Nearly all children with autism spectrum disorders engage in non-functional repetitive vocal and motor behaviours commonly referred to as stereotypy. These repetitive behaviours may considerably interfere with the child's daily functioning, learning, and social inclusion. As such, stereotypy generally has a negative impact on the child and family's health and quality of life. Several behavioural interventions have been developed to reduce engagement in stereotypy in children with autism spectrum disorders, but the limited number of specialists available, the long waiting lists associated with public health services in Canada, and the high costs of private services have considerably restricted accessibility. One potential solution to the limited availability and high costs of services is using a mobile application to recommend, teach, and monitor interventions designed to reduce engagement in stereotypy. To this end, the purpose of the study is to evaluate the effects of the iSTIM (i.e., individualized Stereotypy Treatment Integrated Modules), a mobile application designed to assist parents in reducing stereotypy in children with autism spectrum disorders. Specifically, we will assess whether the iSTIM correctly estimates the frequency or duration of stereotypy, offers suggestions consistent with recommended clinical practices, effectively reduces engagement in stereotypy, and is socially acceptable, safe, and easy to use for parents of children with autism spectrum disorders. The results of the study will allow us to determine whether the mobile application may be used to treat this core symptom in children with autism spectrum disorders, which could potentially reduce waiting times and costs of providing health services to this population. By reducing engagement in stereotypy, the iSTIM may also promote and facilitate the social participation as well as improve the quality of life and health of children with autism spectrum disorders and their families.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Autism Spectrum Disorder
Child Development Disorders, Pervasive
Developmental Disabilities

Clinical Trial Details

NCT number	NCT02124720
Study type	Interventional
Source	Université de Montréal
Contact
Status	Completed
Phase	N/A
Start date	December 2014
Completion date	February 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03222375` - SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism	N/A
Completed	`NCT01233414` - Randomized Trial of Parent Training for Young Children With Autism	N/A
Completed	`NCT00926471` - Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders	Phase 1
Withdrawn	`NCT00376194` - Mercury Chelation to Treat Autism	Phase 2
Completed	`NCT02153203` - Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders	N/A
Completed	`NCT02301195` - Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder	N/A
Completed	`NCT00453180` - A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders	Phase 2
Completed	`NCT04475848` - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants	Phase 1
Terminated	`NCT01517126` - Assessing Suicide Risk in Adolescents With Developmental Delays
Completed	`NCT00080145` - RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders	N/A
Completed	`NCT00166595` - Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)	Phase 1/Phase 2
Completed	`NCT01731119` - Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents	Phase 2
Completed	`NCT00147394` - Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)	Phase 1
Completed	`NCT01921244` - Shared Decision Making to Improve Care and Outcomes for Children With Autism	N/A
Completed	`NCT05688319` - Effect of Problem-Solving Training	N/A
Terminated	`NCT00445471` - A Prospective Study Comparing the Mifne Approach of Treating Childhood Autism With Routine Standard Treatment	N/A
Active, not recruiting	`NCT00110708` - Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.